Foretinib
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Foretinib
Description :
Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Product Name Alternative :
XL880; GSK1363089; GSK089; EXEL-2880UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
C-Met/HGFR; VEGFRType :
Reference compoundRelated Pathways :
Protein Tyrosine Kinase/RTKApplications :
Cancer-Kinase/proteaseField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/Foretinib.htmlConcentration :
10mMPurity :
99.59Solubility :
DMSO : 75 mg/mL (ultrasonic)Smiles :
O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=OMolecular Formula :
C34H34F2N4O6Molecular Weight :
632.65Precautions :
H302, H315, H319, H335References & Citations :
[1]Qian F, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res, 2009, 69 (20), 8009-8016.|[2]Kataoka Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs, 2011.|[3]Eder JP, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res, 2010, 16 (13), 3507-3516.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
Phase 2Isoform :
VEGFR1/Flt-1; VEGFR2/KDR/Flk-1CAS Number :
[849217-64-7]

